FibroGen to Present at Oppenheimer Rare Disease Summit with Key Catalysts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Globenewswire
- Key Conference Participation: FibroGen will attend the Oppenheimer Rare Disease Summit on December 11, 2025, in New York, where CEO Thane Wettig will participate in a panel discussing potential stock-moving catalysts in rare diseases, highlighting the company's strategic focus.
- One-on-One Investor Meetings: The management team will be available for one-on-one meetings during the conference, aiming to attract investor interest in their novel therapies, particularly Roxadustat for chronic kidney disease patients and FG-3246 for prostate cancer treatment.
- New Therapy Development: FibroGen is evaluating the Phase 3 trial plan for Roxadustat in the U.S. targeting lower-risk myelodysplastic syndrome (LR-MDS), which, if successful, could present significant market opportunities for the company.
- Frontier Biopharmaceuticals: As a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia, FibroGen's innovative drugs like FG-3246 and FG-3180 have the potential to transform treatment paradigms, enhancing the company's competitiveness in the biopharmaceutical sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
